Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy
Sponsor: Shaare Zedek Medical Center
A PHASE2 clinical study on Gaucher Disease, Type 1, this trial is completed. The trial is conducted by Shaare Zedek Medical Center and has accumulated 8 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Oct 2021 — Jun 2022 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jun 2019 — Oct 2019 [monthly]
Recruiting PHASE2
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shaare Zedek Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .